ST-506

About Sangamo Therapeutics

Sangamo Therapeutics is a public biotech company focused on translating groundbreaking zinc finger technology into genomic cures for severe diseases with high unmet need. The company has built a diversified pipeline of wholly-owned and partnered programs, primarily in neurology, with key assets in late-stage clinical development for Fabry disease and hemophilia A. Sangamo's strategy combines internal development of neurology-focused therapies with strategic collaborations with major pharmaceutical companies to expand its reach and validate its platform technology.

Therapeutic Areas